Opinion|Videos|March 8, 2024
LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis
Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.
Advertisement
Advertisement
Related to this article
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
3
Dr Van Gorp on PFS Data With TUB-040 in Platinum-Resistant Ovarian Cancer
4
Neoadjuvant Ivonescimab Plus Chemotherapy Yields pCRs in Resectable HNSCC
5